Connecticut 2025 Regular Session

Connecticut Senate Bill SB01473 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1	1
2	2
3		-	LCO 5674 1 of 2
	3	+	LCO No. 5674 1 of 2
4	4
5	5		General Assembly Raised Bill No. 1473
6	6		January Session, 2025
7	7		LCO No. 5674
8	8
9	9
10	10		Referred to Committee on HUMAN SERVICES
11	11
12	12
13	13		Introduced by:
14	14		(HS)
	15	+
15	16
16	17
17	18
18	19		AN ACT REQUIRING MEDICAID COVERAGE FOR FDA -APPROVED
19	20		GENE THERAPIES TO TREAT SICKLE CELL DISEASE.
20	21		Be it enacted by the Senate and House of Representatives in General
21	22		Assembly convened:
22	23
23	24		Section 1. (NEW) (Effective from passage) (a) The Commissioner of 1
24	25		Social Services shall provide Medicaid coverage for gene therapies 2
25	26		approved by the federal Food and Drug Administration to treat sickle 3
26	27		cell disease. 4
27	28		(b) The commissioner shall apply for any federal initiative to increase 5
28	29		cost-effective access to the therapies, including, but not limited to, the 6
29	30		Cell and Gene Therapy Access Model administered by the Centers for 7
30	31		Medicare and Medicaid Services. 8
31	32		(c) Not later than January 1, 2026, the commissioner shall file a report, 9
32	33		in accordance with the provisions of section 11-4a of the general statutes, 10
33	34		with the joint standing committee of the General Assembly having 11
34	35		cognizance of matters relating to human services on the (1) efforts to 12
35	36		increase cost-effective access to the therapies, (2) number of Medicaid 13
36	37		recipients who have received Medicaid coverage for the therapies, (3) 14
37		-	cost to the state to provide such therapies, and (4) estimated state 15 Raised Bill No. 1473
	38	+	cost to the state to provide such therapies, and (4) estimated state 15
	39	+	Raised Bill No. 1473
38	40
39	41
40		-	LCO 5674 2 of 2
	42	+
	43	+	LCO No. 5674 2 of 2
41	44
42	45		appropriations needed to provide such coverage. 16
43	46		This act shall take effect as follows and shall amend the following
44	47		sections:
45	48
46	49		Section 1 from passage New section
47	50
48		-	HS Joint Favorable
	51	+	Statement of Purpose:
	52	+	To require Medicaid coverage for gene therapies approved by the
	53	+	federal Food and Drug Administration to treat sickle cell disease.
	54	+
	55	+	[Proposed deletions are enclosed in brackets. Proposed additions are indicated by underline, except
	56	+	that when the entire text of a bill or resolution or a section of a bill or resolution is new, it is not
	57	+	underlined.]
49	58